BridgeBio Pharma, Inc. Net Income (Loss), Including Portion Attributable to Noncontrolling Interest
BridgeBio Pharma, Inc. (BBIO) reported Net Income (Loss), Including Portion Attributable to Noncontrolling Interest of -$155.89 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-10.
Financial Statements › Income Statement › Net Income
us-gaap:ProfitLoss · last filed 2026-08-10
- BridgeBio Pharma, Inc. net income (loss), including portion attributable to noncontrolling interest for the quarter ending 2026-06-30 was -$155.89M.
- BridgeBio Pharma, Inc. net income (loss), including portion attributable to noncontrolling interest for the quarter ending 2026-03-31 was -$166.56M.
- BridgeBio Pharma, Inc. net income (loss), including portion attributable to noncontrolling interest for the quarter ending 2025-12-31 was -$194.63M.
- BridgeBio Pharma, Inc. net income (loss), including portion attributable to noncontrolling interest for the quarter ending 2025-09-30 was -$184.94M.
- BridgeBio Pharma, Inc. net income (loss), including portion attributable to noncontrolling interest for fiscal 2020 was -$505.49M.
- BridgeBio Pharma, Inc. net income (loss), including portion attributable to noncontrolling interest for fiscal 2019 was -$288.58M.
- BridgeBio Pharma, Inc. net income (loss), including portion attributable to noncontrolling interest for fiscal 2018 was -$169.45M.
- BridgeBio Pharma, Inc. net income (loss), including portion attributable to noncontrolling interest for fiscal 2017 was -$43.83M.
| Period end | Net Income (Loss), Including Portion Attributable to Noncontrolling Interest 3 month | Net Income (Loss), Including Portion Attributable to Noncontrolling Interest 6 month | Net Income (Loss), Including Portion Attributable to Noncontrolling Interest 9 month | Net Income (Loss), Including Portion Attributable to Noncontrolling Interest 12 month | Net Income (Loss), Including Portion Attributable to Noncontrolling Interest 12 month as first filed |
|---|---|---|---|---|---|
| 2026-06-30 | -$155.89M 10-Q · filed 2026-08-10 | -$322.45M 10-Q · filed 2026-08-10 | -$517.08M derived: sum of 3 quarters · filed 2026-08-10 | -$702.02M derived: sum of 4 quarters · filed 2026-08-10 | |
| 2026-03-31 | -$166.56M 10-Q · filed 2026-05-07 | -$361.19M derived: sum of 2 quarters · filed 2026-05-07 | -$546.13M derived: sum of 3 quarters · filed 2026-05-07 | -$729.88M derived: sum of 4 quarters · filed 2026-08-10 | |
| 2025-12-31 | -$194.63M derived: DEF 14A 12 month − 10-Q 9 month · filed 2026-04-24 | -$379.57M derived: sum of 2 quarters · filed 2026-04-24 | -$563.33M derived: sum of 3 quarters · filed 2026-08-10 | -$732.94M DEF 14A · filed 2026-04-24 | |
| 2025-09-30 | -$184.94M 10-Q · filed 2025-10-29 | -$368.69M derived: sum of 2 quarters · filed 2026-08-10 | -$538.30M 10-Q · filed 2025-10-29 | -$805.69M derived: sum of 4 quarters · filed 2026-08-10 | |
| 2025-06-30 | -$183.76M 10-Q · filed 2026-08-10 | -$353.37M 10-Q · filed 2026-08-10 | -$620.75M derived: sum of 3 quarters · filed 2026-08-10 | -$785.01M derived: sum of 4 quarters · filed 2026-08-10 | |
| 2025-03-31 | -$169.61M 10-Q · filed 2026-05-07 | -$437.00M derived: sum of 2 quarters · filed 2026-05-07 | -$601.25M derived: sum of 3 quarters · filed 2026-05-07 | -$676.79M derived: sum of 4 quarters · filed 2026-05-07 | |
| 2024-12-31 | -$267.39M derived: DEF 14A 12 month − 10-Q 9 month · filed 2026-04-24 | -$431.64M derived: sum of 2 quarters · filed 2026-04-24 | -$507.19M derived: sum of 3 quarters · filed 2026-04-24 | -$543.35M DEF 14A · filed 2026-04-24 | |
| 2024-09-30 | -$164.25M 10-Q · filed 2025-10-29 | -$239.80M derived: sum of 2 quarters · filed 2025-10-29 | -$275.96M 10-Q · filed 2025-10-29 | -$446.29M derived: sum of 4 quarters · filed 2026-04-24 | |
| 2024-06-30 | -$75.54M 10-Q · filed 2025-08-05 | -$111.70M 10-Q · filed 2025-08-05 | -$282.03M derived: sum of 3 quarters · filed 2026-04-24 | -$461.52M derived: sum of 4 quarters · filed 2026-04-24 | |
| 2024-03-31 | -$36.16M 10-Q · filed 2025-04-29 | -$206.49M derived: sum of 2 quarters · filed 2026-04-24 | -$385.98M derived: sum of 3 quarters · filed 2026-04-24 | -$546.68M derived: sum of 4 quarters · filed 2026-04-24 | |
| 2023-12-31 | -$170.33M derived: DEF 14A 12 month − 10-Q 9 month · filed 2026-04-24 | -$349.82M derived: sum of 2 quarters · filed 2026-04-24 | -$510.52M derived: sum of 3 quarters · filed 2026-04-24 | -$653.25M DEF 14A · filed 2026-04-24 | |
| 2023-09-30 | -$179.49M 10-Q · filed 2024-11-12 | -$340.19M derived: sum of 2 quarters · filed 2024-11-12 | -$482.92M 10-Q · filed 2024-11-12 | -$623.47M derived: sum of 4 quarters · filed 2026-04-24 | |
| 2023-06-30 | -$160.70M 10-Q · filed 2024-08-01 | -$303.44M 10-Q · filed 2024-08-01 | -$443.98M derived: sum of 3 quarters · filed 2026-04-24 | -$584.17M derived: sum of 4 quarters · filed 2026-04-24 | |
| 2023-03-31 | -$142.73M 10-Q · filed 2024-05-02 | -$283.27M derived: sum of 2 quarters · filed 2026-04-24 | -$423.47M derived: sum of 3 quarters · filed 2026-04-24 | -$426.03M derived: sum of 4 quarters · filed 2026-04-24 | |
| 2022-12-31 | -$140.54M derived: DEF 14A 12 month − 10-Q 9 month · filed 2026-04-24 | -$280.74M derived: sum of 2 quarters · filed 2026-04-24 | -$283.30M derived: sum of 3 quarters · filed 2026-04-24 | -$484.63M DEF 14A · filed 2026-04-24 | -$484.65M 10-K · filed 2023-02-23 |
| 2022-09-30 | -$140.19M 10-Q · filed 2023-11-02 | -$142.75M derived: sum of 2 quarters · filed 2023-11-02 | -$344.08M 10-Q · filed 2023-11-02 | -$496.36M derived: sum of 4 quarters · filed 2026-04-24 | |
| 2022-06-30 | -$2.56M 10-Q · filed 2023-08-03 | -$203.89M 10-Q · filed 2023-08-03 | -$356.17M derived: sum of 3 quarters · filed 2026-04-24 | -$517.19M derived: sum of 4 quarters · filed 2026-04-24 | |
| 2022-03-31 | -$201.33M 10-Q · filed 2023-05-04 | -$353.61M derived: sum of 2 quarters · filed 2026-04-24 | -$514.63M derived: sum of 3 quarters · filed 2026-04-24 | -$616.70M derived: sum of 4 quarters · filed 2026-04-24 | |
| 2021-12-31 | -$152.28M derived: DEF 14A 12 month − 10-Q 9 month · filed 2026-04-24 | -$313.30M derived: sum of 2 quarters · filed 2026-04-24 | -$415.37M derived: sum of 3 quarters · filed 2026-04-24 | -$586.45M DEF 14A · filed 2026-04-24 | |
| 2021-09-30 | -$161.02M 10-Q · filed 2022-11-03 | -$263.09M derived: sum of 2 quarters · filed 2022-11-03 | -$434.17M 10-Q · filed 2022-11-03 | -$569.20M derived: sum of 4 quarters · filed 2023-02-23 | |
| 2021-06-30 | -$102.07M 10-Q · filed 2022-08-04 | -$273.16M 10-Q · filed 2022-08-04 | -$408.18M derived: sum of 3 quarters · filed 2023-02-23 | -$538.35M derived: sum of 4 quarters · filed 2023-02-23 | |
| 2021-03-31 | -$171.08M 10-Q · filed 2022-05-05 | -$306.11M derived: sum of 2 quarters · filed 2023-02-23 | -$436.27M derived: sum of 3 quarters · filed 2023-02-23 | -$572.49M derived: sum of 4 quarters · filed 2023-02-23 | |
| 2020-12-31 | -$135.03M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-23 | -$265.19M derived: sum of 2 quarters · filed 2023-02-23 | -$401.41M derived: sum of 3 quarters · filed 2023-02-23 | -$505.49M 10-K · filed 2023-02-23 | |
| 2020-09-30 | -$130.17M 10-Q · filed 2021-11-04 | -$266.38M derived: sum of 2 quarters · filed 2021-11-04 | -$370.46M 10-Q · filed 2021-11-04 | -$454.61M derived: sum of 4 quarters · filed 2022-02-25 | |
| 2020-06-30 | -$136.21M 10-Q · filed 2021-08-05 | -$240.30M 10-Q · filed 2021-08-05 | -$324.45M derived: sum of 3 quarters · filed 2022-02-25 | -$385.11M derived: sum of 4 quarters · filed 2022-02-25 | |
| 2020-03-31 | -$104.08M 10-Q · filed 2021-05-06 | -$188.23M derived: sum of 2 quarters · filed 2022-02-25 | -$248.90M derived: sum of 3 quarters · filed 2022-02-25 | -$323.23M derived: sum of 4 quarters · filed 2022-02-25 | |
| 2019-12-31 | -$84.15M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-25 | -$144.81M derived: sum of 2 quarters · filed 2022-02-25 | -$219.15M derived: sum of 3 quarters · filed 2022-02-25 | -$288.58M 10-K · filed 2022-02-25 | |
| 2019-09-30 | -$60.66M 10-Q · filed 2020-11-05 | -$135.00M derived: sum of 2 quarters · filed 2020-11-05 | -$204.43M 10-Q · filed 2020-11-05 | -$253.68M derived: sum of 4 quarters · filed 2021-02-25 | |
| 2019-06-30 | -$74.33M 10-Q · filed 2020-08-11 | -$143.77M 10-Q · filed 2020-08-11 | -$193.01M derived: sum of 3 quarters · filed 2021-02-25 | -$235.09M derived: sum of 4 quarters · filed 2021-02-25 | |
| 2019-03-31 | -$69.44M 10-Q · filed 2020-05-14 | -$118.68M derived: sum of 2 quarters · filed 2021-02-25 | -$160.75M derived: sum of 3 quarters · filed 2021-02-25 | ||
| 2018-12-31 | -$49.24M derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-25 | -$91.32M derived: sum of 2 quarters · filed 2021-02-25 | -$169.45M 10-K · filed 2021-02-25 | ||
| 2018-09-30 | -$42.08M 10-Q · filed 2019-11-08 | -$120.21M 10-Q · filed 2019-11-08 | |||
| 2017-12-31 | -$43.83M 10-K · filed 2020-03-03 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |